Table 1 Demographics of Respondents and Vaccination details
Completed COVID questionnaire (n = 189) | p-value | ||
|---|---|---|---|
|  | Personal history of cancer (N = 130) | Nil history of cancer (N = 59) | |
Gender | |||
 Female | 124 (95%) | 38 (64%) | < 0.001+ |
 Male | 6 (5%) | 21 (36%) | |
Race | |||
 Chinese | 84 (65%) | 44 (75%) | 0.152* |
 Malay | 21 (16%) | 7 (12%) | |
 Indian | 13 (10%) | 3 (5%) | |
 Others | 12 (9%) | 4 (7%) | |
 Unspecified | 0 | 1 (2%) | |
Age, years | |||
 Median (Range) | 53.5 (28–79) | 42.5 (22–77) | < 0.001# |
 Mean (SD) | 53.5 (±11.7) | 45.7 (±14.0) | |
Germline pathogenic gene | |||
 BRCA1 | 65 (50%) | 32 (54%) | 0.531+ |
 BRCA2 | 65 (50%) | 27 (46%) | |
Types of cancer | |||
 Breast | 78 (60%) | NA |  |
 Ovarian | 28 (22%) |  |  |
 Others | 7 (5%) |  |  |
 More than 1 cancer | 16 (12%) |  |  |
 Unspecified/No cancer | 1 (1%) |  |  |
COVID Vaccination | |||
 Yes | 116 (89%) | 54 (92%) | 0.796+ |
  1 dose | 11 (8%) | 1 (2%) |  |
  2 doses | 105 (81%) | 51 (86%) |  |
  Unspecified | 0 (0%) | 2 (3%) |  |
 No | 14 (11%) | 5 (8%) |  |
Previous COVID-19 | |||
 Yes | 2 (2%) | 0 (0%) | 1.000* |
 No | 125 (96%) | 59 (100%) |  |
 Unspecified | 3 (2%) | 0 (0%) |  |
Vaccinated individuals | |||
 Type of Vaccination | N = 116 | N = 54 | 0.806* |
  Pfizer | 97 (84%) | 47 (87%) |  |
  Moderna | 13 (11%) | 7 (13%) |  |
  Sinovac | 3 (3%) | 0 (0%) |  |
  Unspecified | 3 (3%) | 0 (0%) |  |
Side effects post vaccination | Â | ||
 Yes | 64 (55%) | 28 (54%) | 0.740+ |
  1 side effect | 36 (31%) | 15 (28%) |  |
  2 side effects | 20 (17%) | 14 (26%) |  |
  Multiple (> 2) side effects | 8 (7%) | 0 (%) |  |
 No | 50 (43%) | 25 (46%) |  |
  Unreported | 2 (2%) | 0 (%) |  |